Clinical trial · Observational
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775CI-TRIAL-00084267recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- patients diagnosed with DLBCL who will receive immunotherapy (CAR-T, glofitamab, iR2)
Primary outcomes (2)
- measure
- The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
- timeFrame
- Baseline and 2 weeks after treatment
- description
- The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
- measure
- Standardized uptake value (SUV)
- timeFrame
- Baseline and 2 weeks after treatment
- description
- SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Secondary outcomes (2)
- measure
- Progress free suivival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form Exclusion Criteria: 1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant
References
Publications (0)
Data not yet available
No reference posted for this study.